Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 6/2019

01-11-2019 | Diabetic Cardiomyopathy

A review of fibroblast growth factor 21 in diabetic cardiomyopathy

Authors: Xiang Zhang, Luo Yang, Xiongfeng Xu, Fengjuan Tang, Peng Yi, Bo Qiu, Yarong Hao

Published in: Heart Failure Reviews | Issue 6/2019

Login to get access

Abstract

FGF21 (fibroblast growth factor 21) is a regulator of metabolism and performs an important role in glucose and lipid metabolism and the maintenance of energy balance. FGF21 is principally expressed in the liver, but it can also be found in the pancreas, skeletal muscle, and adipose tissue. It is known that levels of serum FGF21 are significantly elevated in obese, insulin-resistant patients, and those with metabolic syndrome. Elevated levels of FGF21 in serum during the early stages of various metabolic diseases are considered a compensatory response by the organism. Therefore, FGF21 is considered a hormone in response to stress and an early diagnostic marker of disease. Diabetic cardiomyopathy is a special type of cardiac complication, characterized as a chronic myocardial disorder caused by diabetes. The pathological process includes increased oxidative stress, energy metabolism in myocardial cells, an inflammatory response, and myocardial cell apoptosis. A growing body of evidence suggests that FGF21 has the potential to be an effective drug for the treatment of diabetic cardiomyopathy. Here, we review recent progress on the characteristics of FGF21 in its protective role, especially in pathological processes such as suppressing apoptosis in the myocardium, reducing inflammation in cardiomyocytes, reducing oxidative stress, and promoting fatty acid oxidation. In addition, we explore the possibility that diabetic cardiomyopathy can be delayed through the application of FGF21, providing possible therapeutic targets of the disease.
Literature
1.
Staiger H, Keuper M, Berti L, Hrabe DAM, Haring HU (2017 2017-10-01) Fibroblast growth factor 21-metabolic role in mice and men. Endocr Rev 38(5):468–488PubMedCrossRef
2.
Recinella L, Leone S, Ferrante C et al (2017 2017-07-01) Effects of central fibroblast growth factor 21 (FGF21) in energy balance. J Biol Regul Homeost Agents 31(3):603–613PubMed
3.
Sheehan SM, Allen RE (1999 1999-12-01) Skeletal muscle satellite cell proliferation in response to members of the fibroblast growth factor family and hepatocyte growth factor. J Cell Physiol 181(3):499–506PubMedCrossRef
4.
Krejci P, Prochazkova J, Bryja V, Kozubik A, Wilcox WR (2009 2009-09-01) Molecular pathology of the fibroblast growth factor family. Hum Mutat 30(9):1245–1255PubMedPubMedCentralCrossRef
5.
Itoh N, Ornitz DM (2008 2008-01-01) Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237(1):18PubMedCrossRef
6.
Nishimura T, Nakatake Y, Konishi M, Itoh N (2000 2000-06-21) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492(1):203–206PubMedCrossRef
7.
Hondares E, Iglesias R, Giralt A et al (2011 2011-04-15) Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 286(15):12983–12990PubMedPubMedCentralCrossRef
8.
9.
Wente W, Efanov AM, Brenner M et al (2006 2006-09-01) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55(9):2470–2478PubMedCrossRef
10.
Yoon JH, Kim J, Song P, Lee TG, Suh PG, Ryu SH (2012 2012-05-01) Secretomics for skeletal muscle cells: a discovery of novel regulators? Adv Biol Regul 52(2):340–350PubMedCrossRef
11.
Zhang C, Huang Z, Gu J et al (2015 2015-08-01) Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetologia 58(8):1937–1948PubMedCrossRef
12.
Bookout AL, de Groot MH, Owen BM et al (2013 2013-09-01) FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19(9):1147–1152PubMedPubMedCentralCrossRef
13.
Yamaguchi TP, Rossant J (1995 1995-08-01) Fibroblast growth factors in mammalian development. Curr Opin Genet Dev 5(4):485–491PubMedCrossRef
14.
Eswarakumar VP, Lax I, Schlessinger J (2005 2005-04-01) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16(2):139–149PubMedCrossRef
15.
Goetz R, Beenken A, Ibrahimi OA et al (2007 2007-05-01) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27(9):3417–3428PubMedPubMedCentralCrossRef
16.
Urakawa I, Yamazaki Y, Shimada T et al (2006 2006-12-07) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444(7120):770–774PubMedCrossRef
17.
Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP. β Klotho is required for metabolic activity of fibroblast growth factor 21
18.
Holt JA, Luo G, Billin AN et al (2003 2003-07-01) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17(13):1581–1591PubMedPubMedCentralCrossRef
19.
Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM (2006 2006-06-09) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281(23):15694–15700PubMedCrossRef
20.
Yie J, Hecht R, Patel J et al (2009 2009-01-05) FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 583(1):19–24PubMedCrossRef
21.
Ogawa Y, Kurosu H, Yamamoto M et al (2007 2007-05-01) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 104(18):7432–7437PubMedPubMedCentralCrossRef
22.
Yie J, Wang W, Deng L et al (2012 2012-04-01) Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: structural requirements and implications in FGF21 signaling. Chem Biol Drug Des 79(4):398–410PubMedCrossRef
23.
Yang W, Chen X, Liu Y et al (2017 2017-09-01) N-3 polyunsaturated fatty acids increase hepatic fibroblast growth factor 21 sensitivity via a PPAR-gamma-beta-klotho pathway. Mol Nutr Food Res 61(9)
24.
Kobayashi K, Tanaka T, Okada S et al (2016 2016-02-01) Hepatocyte beta-Klotho regulates lipid homeostasis but not body weight in mice. FASEB J 30(2):849–862PubMedCrossRef
25.
Markan KR, Naber MC, Small SM, Peltekian L, Kessler RL, Potthoff MJ (2017 2017-06-01) FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue. Mol Metab 6(6):602–610PubMedPubMedCentralCrossRef
26.
Lin Z, Pan X, Wu F et al (2015 2015-05-26) Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131(21):1861–1871PubMedPubMedCentralCrossRef
27.
Lee Y, Lim S, Hong ES et al (2014 2014-01-01) Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf) 80(1):57–64CrossRef
28.
Cuevas-Ramos D, Aguilar-Salinas CA (2016 2016-06-20) Modulation of energy balance by fibroblast growth factor 21. Horm Mol Biol Clin Investig 30(1)
29.
Kruse R, Vienberg SG, Vind BF, Andersen B, Hojlund K (2017 2017-10-01) Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes. Diabetologia 60(10):2042–2051PubMedCrossRef
30.
Velasco I, Santos C, Limon J et al (2016 2016-01-20) Bioactive components in human milk along the first month of life: effects of iodine supplementation during pregnancy. Ann Nutr Metab 68(2):130–136PubMedCrossRef
31.
Esteghamati A, Khandan A, Momeni A et al (2017 2017-08-01) Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease. Ir J Med Sci 186(3):785–794PubMedCrossRef
32.
Cheng P, Zhang F, Yu L et al (2016 2016-01-20) Physiological and pharmacological roles of FGF21 in cardiovascular diseases. J Diabetes Res 2016:1540267PubMedPubMedCentral
33.
Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R (2017 2017-11-01) Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther 179:171–187PubMedCrossRef
34.
Itoh N, Ohta H, Nakayama Y, Konishi M (2016 2016-01-20) Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol 4:110PubMedPubMedCentral
35.
Olszanecka-Glinianowicz M, Madej P, Wdowczyk M, Owczarek A, Chudek J (2015 2015-02-01) Circulating FGF21 levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome. Eur J Endocrinol 172(2):173–179PubMedCrossRef
36.
Su SL, Wang WF, Wu SL et al (2012 2012-12-24) FGF21 in ataxia patients with spinocerebellar atrophy and mitochondrial disease. Clin Chim Acta 414:225–227PubMedCrossRef
37.
Restelli LM, Oettinghaus B, Halliday M et al (2018 2018-08-07) Neuronal mitochondrial dysfunction activates the integrated stress response to induce fibroblast growth factor 21. Cell Rep 24(6):1407–1414PubMedPubMedCentralCrossRef
38.
Cai G, Liu J, Wang M et al (2019 2019-03-01) Mutual promotion of FGF21 and PPARgamma attenuates hypoxia-induced pulmonary hypertension. Exp Biol Med (Maywood) 244(3):252–261PubMedCentralCrossRef
39.
Cieszynski L, Berendt-Obolonczyk M, Szulc M, Sworczak K (2016 2016-01-20) Cushing's syndrome due to ectopic ACTH secretion. Endokrynol Pol 67(4):458–471PubMed
40.
Li Z, Zhang T, Dai H et al (2008 2008-03-01) Endoplasmic reticulum stress is involved in myocardial apoptosis of streptozocin-induced diabetic rats. J Endocrinol 196(3):565–572PubMedCrossRef
41.
Yang H, Feng A, Lin S et al (2018 2018-02-14) Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell Death Dis 9(2):227PubMedPubMedCentralCrossRef
42.
Cong WT, Ling J, Tian HS et al (2013 2013-11-01) Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury. Can J Physiol Pharmacol 91(11):973–984PubMedCrossRef
43.
Liang P, Zhong L, Gong L et al (2017 2017-01-01) Fibroblast growth factor 21 protects rat cardiomyocytes from endoplasmic reticulum stress by promoting the fibroblast growth factor receptor 1-extracellular signal-regulated kinase 1/2 signaling pathway. Int J Mol Med 40(5):1477–1485PubMedPubMedCentralCrossRef
44.
45.
Xu P, Zhang Y, Liu Y et al (2016 2016-01-01) Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-beta/smad2/3 and NF-kappaB signaling pathways. Toxicol Appl Pharmacol 290:43–53PubMedCrossRef
46.
Wu JH, Batist G (2013 2013-05-01) Glutathione and glutathione analogues; therapeutic potentials. Biochim Biophys Acta 1830(5):3350–3353PubMedCrossRef
47.
Gomez-Samano MA, Grajales-Gomez M, Zuarth-Vazquez JM et al (2017 2017-04-01) Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol 11:335–341PubMedCrossRef
48.
Matuszek B, Lenart-Lipinska M, Duma D, Solski J, Nowakowski A (2010 2010-01-01) Evaluation of concentrations of FGF-21—a new adipocytokine in type 2 diabetes. Endokrynol Pol 61(1):50–54PubMed
49.
Li X, Yu H, Yin J et al (2017 2017-02-22) Decreased levels of fibroblast growth factor 21 are correlated with improved hypoglycemia in patients with insulinoma. Sci Rep 7:43123PubMedPubMedCentralCrossRef
50.
Bauters C, Lamblin N, Mc FE, Van Belle E, Millaire A, de Groote P (2003 2003-01-08) Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2:1PubMedPubMedCentralCrossRef
51.
Vrtovec B, Sever M, Jensterle M et al (2016 2016-05-01) Efficacy of CD34+ stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance. Stem Cells Transl Med 5(5):632–638PubMedPubMedCentralCrossRef
52.
Luo JW, Zheng X, Cheng GC, Ye QH, Deng YZ, Wu L (2016 2016-10-01) Resistin-induced cardiomyocyte hypertrophy is inhibited by apelin through the inactivation of extracellular signal-regulated kinase signaling pathway in H9c2 embryonic rat cardiomyocytes. Biomed Rep 5(4):473–478PubMedPubMedCentralCrossRef
53.
Xu T, Liu Y, Deng Y et al (2016 2016-07-01) [Insulin combined with selenium inhibit p38MAPK/CBP pathway and suppresses cardiomyocyte apoptosis in rats with diabetic cardiomyopathy]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 32(7):926–930PubMed
54.
Yue Y, Meng K, Pu Y, Zhang X (2017 2017-09-01) Transforming growth factor beta (TGF-beta) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract 133:124–130PubMedCrossRef
55.
Alonso N, Moliner P, Mauricio D (2017) Pathogenesis, clinical features and treatment of diabetic cardiomyopathy. Adv Exp Med Biol. 2017-10-05
56.
Jia G, Whaley-Connell A, Sowers JR (2017) Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2017-08-03
57.
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972 1972-11-08) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30(6):595–602PubMedCrossRef
58.
Galderisi M (2006 2006-10-17) Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 48(8):1548–1551PubMedCrossRef
59.
Gu Y, Warren J, Walker N, Kennelly J (2013 2013-01-20) Gender differences in cardiovascular disease risk management for Pacific Islanders in primary care. Qual Prim Care 21(5):275–285PubMed
60.
Shao M, Yu L, Zhang F et al (2015 2015-07-01) Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model. Am J Physiol Endocrinol Metab 309(1):E45–E54PubMedPubMedCentralCrossRef
61.
Sung MM, Hamza SM, Dyck JR (2015 2015-06-10) Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets. Antioxid Redox Signal 22(17):1606–1630PubMedCrossRef
62.
Bell D, Goncalves E (2019) Heart failure in the patient with diabetes: epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. Diabetes Obes Metab. 2019-02-05
63.
Schutt K, Marx N (2019) Heart failure and diabetes: management and open issues. Herz. 2019-03-07
64.
Lei S, Li H, Xu J et al (2013 2013-07-01) Hyperglycemia-induced protein kinase C beta2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling. Diabetes 62(7):2318–2328PubMedPubMedCentralCrossRef
65.
Lee Y, Gustafsson AB (2009 2009-04-01) Role of apoptosis in cardiovascular disease. Apoptosis 14(4):536–548PubMedCrossRef
66.
Austin RC (2009 2009-09-01) The unfolded protein response in health and disease. Antioxid Redox Signal 11(9):2279–2287PubMedCrossRef
67.
Makela J, Tselykh TV, Maiorana F et al (2014 2014-01-20) Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1alpha in human dopaminergic neurons via Sirtuin-1. SpringerPlus 3:2PubMedPubMedCentralCrossRef
68.
Kim I, Xu W, Reed JC (2008 2008-12-01) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7(12):1013–1030PubMedCrossRef
69.
Minamino T, Komuro I, Kitakaze M (2010 2010-10-29) Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res 107(9):1071–1082PubMedCrossRef
70.
Minamino T, Kitakaze M (2010 2010-06-01) ER stress in cardiovascular disease. J Mol Cell Cardiol 48(6):1105–1110PubMedCrossRef
71.
Wan XS, Lu XH, Xiao YC et al (2014 2014-01-20) ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. Biomed Res Int 2014:807874PubMedPubMedCentral
72.
Rao RV, Peel A, Logvinova A et al (2002 2002-03-13) Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett 514(2–3):122–128PubMedPubMedCentralCrossRef
73.
Urano F, Wang X, Bertolotti A et al (2000 2000-01-28) Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287(5453):664–666PubMedCrossRef
74.
Ye M, Lu W, Wang X et al (2016 2016-12-01) FGF21-FGFR1 coordinates phospholipid homeostasis, lipid droplet function, and ER stress in obesity. Endocrinology 157(12):4754–4769PubMedCrossRef
75.
Winder WW, Thomson DM (2007 2007-01-20) Cellular energy sensing and signaling by AMP-activated protein kinase. Cell Biochem Biophys 47(3):332–347PubMedCrossRef
76.
Ojuka EO (2004 2004-05-01) Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc 63(2):275–278PubMedCrossRef
77.
Beauloye C, Bertrand L, Horman S, Hue L (2011 2011-05-01) AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 90(2):224–233PubMedCrossRef
78.
Morrison A, Li J (2011 2011-08-01) PPAR-gamma and AMPK—advantageous targets for myocardial ischemia/reperfusion therapy. Biochem Pharmacol 82(3):195–200PubMedCrossRef
79.
Asare Y, Shagdarsuren E, Schmid JA et al (2013 2013-07-01) Endothelial CSN5 impairs NF-kappaB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. Thromb Haemost 110(1):141–152PubMedCrossRef
80.
81.
Frati G, Schirone L, Chimenti I et al (2017 2017-03-15) An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc Res 113(4):378–388PubMedCrossRef
82.
Datta SR, Brunet A, Greenberg ME (1999 1999-11-15) Cellular survival: a play in three Akts. Genes Dev 13(22):2905–2927PubMedCrossRef
83.
Shiojima I, Walsh K (2006 2006-12-15) Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 20(24):3347–3365PubMedCrossRef
84.
85.
Yu Y, Zheng G (2017 2017-06-01) Troxerutin protects against diabetic cardiomyopathy through NFkappaB/AKT/IRS1 in a rat model of type 2 diabetes. Mol Med Rep 15(6):3473–3478PubMedPubMedCentralCrossRef
86.
Kotulak T, Drapalova J, Kopecky P et al (2011 2011-01-20) Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiol Res 60(5):757–767PubMedCrossRef
87.
Planavila A, Redondo I, Hondares E et al (2013 2013-01-20) Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4:2019PubMedCrossRef
88.
89.
Sasaki S, Inoguchi T (2012 2012-08-01) The role of oxidative stress in the pathogenesis of diabetic vascular complications. Diabetes Metab J 36(4):255–261PubMedPubMedCentralCrossRef
90.
Ahmad W, Ijaz B, Shabbiri K, Ahmed F, Rehman S (2017 2017-09-19) Oxidative toxicity in diabetes and Alzheimer's disease: mechanisms behind ROS/ RNS generation. J Biomed Sci 24(1):76PubMedPubMedCentralCrossRef
91.
Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM (2003 2003-08-12) Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108(6):754–759PubMedCrossRef
92.
Schleicher E, Friess U (2007 2007-08-01) Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl 106:S17–S26CrossRef
93.
Zhu K, Kakehi T, Matsumoto M et al (2015 2015-06-01) NADPH oxidase NOX1 is involved in activation of protein kinase C and premature senescence in early stage diabetic kidney. Free Radic Biol Med 83:21–30PubMedCrossRef
94.
Lacraz G, Figeac F, Movassat J et al (2009 2009-08-05) Diabetic beta-cells can achieve self-protection against oxidative stress through an adaptive up-regulation of their antioxidant defenses. Plos One 4(8):e6500PubMedPubMedCentralCrossRef
95.
Koh G, Yang EJ, Kim MK, Lee SA, Lee DH (2013 2013-01-20) Alpha-lipoic acid treatment reverses 2-deoxy-D-ribose-induced oxidative damage and suppression of insulin expression in pancreatic beta-cells. Biol Pharm Bull 36(10):1570–1576PubMedCrossRef
96.
Liu P, Su J, Song X, Wang S (2017 2017-12-02) Activation of nuclear beta-catenin/c-Myc axis promotes oxidative stress injury in streptozotocin-induced diabetic cardiomyopathy. Biochem Biophys Res Commun 493(4):1573–1580PubMedCrossRef
97.
Guldiken B, Demir M, Guldiken S, Turgut N, Turgut B, Tugrul A (2009 2009-12-01) Oxidative stress and total antioxidant capacity in diabetic and nondiabetic acute ischemic stroke patients. Clin Appl Thromb Hemost 15(6):695–700PubMedCrossRef
98.
Kang KW, Lee SJ, Park JW, Kim SG (2002 2002-11-01) Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol Pharmacol 62(5):1001–1010PubMedCrossRef
99.
Zhang Q, Huang WD, Lv XY, Yang YM (2012 2012-05-01) Puerarin protects differentiated PC12 cells from H(2)O(2)-induced apoptosis through the PI3K/Akt signalling pathway. Cell Biol Int 36(5):419–426PubMedCrossRef
100.
Fu J, Huang H, Liu J, Pi R, Chen J, Liu P (2007 2007-07-30) Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 568(1–3):213–221PubMedCrossRef
101.
Gustafsson AB, Gottlieb RA (2003 2003-11-01) Mechanisms of apoptosis in the heart. J Clin Immunol 23(6):447–459PubMedCrossRef
102.
Tabassum H, Parvez S, Pasha ST, Banerjee BD, Raisuddin S (2010 2010-07-01) Protective effect of lipoic acid against methotrexate-induced oxidative stress in liver mitochondria. Food Chem Toxicol 48(7):1973–1979PubMedCrossRef
103.
Adams JM, Cory S (1998 1998-08-28) The Bcl-2 protein family: arbiters of cell survival. Science 281(5381):1322–1326PubMedCrossRef
104.
Sun Y, Su Q, Li L, Wang X, Lu Y, Liang J (2017 2017-05-10) MiR-486 regulates cardiomyocyte apoptosis by p53-mediated BCL-2 associated mitochondrial apoptotic pathway. BMC Cardiovasc Disord 17(1):119PubMedPubMedCentralCrossRef
105.
Han MM, Wang WF, Liu MY et al (2014 2014-04-01) FGF-21 protects H9c2 cardiomyoblasts against hydrogen peroxide-induced oxidative stress injury. Yao Xue Xue Bao 49(4):470–475PubMed
106.
Yu Y, Li S, Liu Y et al (2015 2015-03-01) Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway. Int Immunopharmacol 25(1):74–82PubMedCrossRef
107.
Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A (2011 2011-10-07) Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem 286(40):34533–34541PubMedPubMedCentralCrossRef
108.
Yan X, Chen J, Zhang C et al (2015 2015-07-01) FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J Cell Mol Med 19(7):1557–1568PubMedPubMedCentralCrossRef
109.
Potthoff MJ, Inagaki T, Satapati S et al (2009 2009-06-30) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 106(26):10853–10858PubMedPubMedCentralCrossRef
110.
Bugger H, Abel ED (2009 2009-09-01) Rodent models of diabetic cardiomyopathy. Dis Model Mech 2(9–10):454–466PubMedCrossRef
111.
Xiao Y, Xu A, Law LS et al (2012 2012-01-01) Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 97(1):E54–E58PubMedCrossRef
112.
Yang J, Sambandam N, Han X et al (2007 2007-04-27) CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 100(8):1208–1217PubMedCrossRef
113.
Geloen A, Helin L, Geeraert B, Malaud E, Holvoet P, Marguerie G (2012 2012-01-20) CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis. Plos One 7(5):e37633PubMedPubMedCentralCrossRef
114.
Luiken JJ, Coort SL, Koonen DP et al (2004 2004-04-01) Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch 448(1):1–15PubMedCrossRef
115.
Greenwalt DE, Scheck SH, Rhinehart-Jones T (1995 1995-09-01) Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin Invest 96(3):1382–1388PubMedPubMedCentralCrossRef
116.
Fukuda T, Fukui M, Tanaka M et al (2015 2015-05-01) Effect of Brazilian green propolis in patients with type 2 diabetes: a double-blind randomized placebo-controlled study. Biomed Rep 3(3):355–360PubMedPubMedCentralCrossRef
117.
Pham T, Loiselle D, Power A, Hickey AJ (2014 2014-09-15) Mitochondrial inefficiencies and anoxic ATP hydrolysis capacities in diabetic rat heart. Am J Physiol Cell Physiol 307(6):C499–C507PubMedCrossRef
118.
Mori J, Patel VB, Abo AO et al (2014 2014-03-01) Angiotensin 1–7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 7(2):327–339PubMedCrossRef
119.
Ilkun O, Boudina S (2013 2013-01-20) Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies. Curr Pharm Des 19(27):4806–4817PubMedPubMedCentralCrossRef
Metadata
Title
A review of fibroblast growth factor 21 in diabetic cardiomyopathy
Authors
Xiang Zhang
Luo Yang
Xiongfeng Xu
Fengjuan Tang
Peng Yi
Bo Qiu
Yarong Hao
Publication date
01-11-2019
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 6/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-019-09809-x

Other articles of this Issue 6/2019

Heart Failure Reviews 6/2019 Go to the issue

ReviewPaper

Advances in targeted therapy for chronic thromboembolic pulmonary hypertension

ReviewPaper

Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors

ReviewPaper

Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study

ReviewPaper

Takotsubo syndrome: an overview of pathophysiology, diagnosis and treatment with emphasis on cancer patients

ReviewPaper

Biomarkers in heart failure: the past, current and future

ReviewPaper

Advances in research on treatment of heart failure with nitrosyl hydrogen

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits